Table 3.
Baseline characteristics of the matched patient cohorts.
| Variable | TIPS | No TIPS | p Value |
|---|---|---|---|
| Number | 216 | 216 | |
| Age, years (IQR) | 58 (51–65) | 58 (50–65) | 0.760 |
| Sex, m/f | 141/75 | 141/75 | 1.000 |
| MELD (IQR) | 12 (10–14.8) | 11.7 (9.2–14.4) | 0.581 |
| f/u, months ± SD | 85.3 ± 266.7 | 42.9 ± 25.6 | <0.0001 |
| Covered/bare metal, n | 159/57 | ||
| Prior episode of HE | 24 (11%) | 14 (4.6%) | 0.069 |
| Underlying diseases in patients | |||
| Alcohol | 113 | 113 | 1.000 |
| NASH | 23 | 23 | 1.000 |
| Viral hepatitis | 1.000 | ||
| HBV | 7 | 10 | 0.452 |
| HCV | 24 | 22 | 0.768 |
| Cryptogenic | 21 | 11 | 0.069 |
| Wilson disease | 1 | 1 | 0.997 |
| Haemochromatosis | 13 | 10 | 0.528 |
| Budd-Chiari | 5 | 1 | 0.102 |
| Osler disease | 0 | 0 | 1.000 |
| PBC | 9 | 15 | 0.204 |
| PSC | 19 | 5 | 0.003 |
| SSC | 7 | 8 | 0.786 |
| Autoimmune hepatitis | 9 | 8 | 0.812 |
| Polycystic liver disease | 0 | 0 | 1.000 |
| Chronic portal vein thrombosis | 4 | 2 | 0.415 |
| CASH/DILI | 1 | 5 | 0.102 |
| HCC, n | 8 | 24 | 0.003 |
| HCC location, n (%) | 0.217 | ||
| Left lobe | 0 (0) | 5 (21) | |
| Right lobe | 7 (87,5) | 17 (71) | |
| Bilobular | 1 (12.5) | 2 (8) | |
| Extrahepatic spread, n (%) | 1 (12.5) | 6 (25) | 0.637 |
| Vascular infiltration, n (%) | 0 (0) | 1 (4) | 0.610 |
| HCC size, cm ± SD | 3.44 ± 1.76 | 5.63 ± 3.44 | 0.071 |
| HCC Nodules, n (IQR) | 1 (1–1.25) | 2 (1–3) | 0.066 |
| BCLC, n | 0.293 | ||
| Stage 0 | 0 | 2 | |
| Stage A | 5 | 11 | |
| Stage B | 0 | 3 | |
| Stage C | 1 | 8 | |
| Serum AFP, median (IQR) | 35 (4.4–1660) | 30.5 (7.5–496) | 0.767 |
| Laboratory parameters, median (IQR) | |||
| Serum bilirubin, mg/dl | 1.2 (0.8–1.9) | 1.5 (0.8–2.4) | 0.090 |
| INR | 1.3 (1.15–1.44) | 1.2 (1.03–1.4) | <0.0001 |
| Creatinine, mg/dl | 1 (0.8–1.3) | 1 (0.73–1.3) | 0.531 |
AFP: alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer Staging System; CASH: chemotherapy-associated steatohepatitis; DILI: drug-induced liver injury; f/u: follow-up; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HE: hepatic encephalopathy; INR: international normalized ratio; IQR: interquartile range (25–75 percentile); MELD: model of liver end-stage disease; NASH: non-alcoholic steatohepatitis; PBC: primary biliary cholangitis; PSC: primary sclerosing cholangitis; SD: standard deviation; SSC: secondary sclerosing cholangitis.